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Abstract 
Purpose: The aim of this narrative review is to outline the mechanism of action of HFNC therapy, the clinical benefits of its use, 
cautions of its clinical application and limitations of previous research. Methods: A literature review was conducted using the 
following databases as sources: Medline, PubMed, and Google Scholar. Only publications written in English were used in this 
clinical review. Keywords used in the search included the following: high-flow nasal cannula, heated humidified oxygen, oxygen 
therapy, non-invasive ventilation, and respiratory failure. Results: The literature reveals HFNC therapy significantly decreased the 
use of mechanical ventilation (invasive or non-invasive) in patients experiencing respiratory failure. HFNC therapy was better 
tolerated by patients and decreased the patient’s work of breathing when compared to a conventional oxygen therapy (i.e., non-
rebreather oxygen mask). Other clinical benefits of using HFNC when changing a patient from conventional facemask oxygen 
therapy to a HFNC device are significant improvements in PaO2, respiratory rate, and overall comfort. Conclusions: High flow 
nasal cannula (HFNC) therapy serves as an alternative to conventional oxygen therapy to deliver elevated concentrations of 
oxygen to patients experiencing acute respiratory failure. Information detailed in this article suggests HFNC therapy is an effective 
therapy for improving a patient’s oxygenation status when experiencing acute respiratory failure in adults. The literature reveals 
that it is reasonable to initiate HFNC in adults with acute hypoxemic respiratory failure without hypercapnia as an alternative to 
standard oxygen therapy or noninvasive positive pressure ventilation.  
 
INTRODUCTION 
Oxygen therapy is the primary treatment for patients suffering from hypoxemia.1,2 Conventional forms of oxygen therapy utilize 
various delivery interfaces while supplying increased concentrations of oxygen above ambient levels. Considered an alternative 
to these oxygenation modalities, high-flow nasal cannula (HFNC) devices were developed to supply the patient with above 
ambient levels of oxygen concentrations while delivering heated humidified gas at inspiratory flow rates of up to 60 lpm. 
Numerous clinic trials have reported increased patient comfort and therapeutic benefits of HFNC therapy, particularly in patients 
suffering from respiratory failure secondary to hypoxemia.3-5 In contrast to the published research outlining the therapeutic 
benefits of HFNC therapy, other researchers argue the delay of invasive and non-invasive ventilation strategies is linked to HFNC 
therapy.6 Similarly, limitations to previous HFNC research also create room for caution.7  
 
It is well established in medicine that oxygen therapy is the drug of choice for patients with low oxygen saturation. The gap that 
exists, in our opinion, is on the specific role of HFNC therapy as an adjunct for oxygen delivery. The theoretical framework for 
this narrative review is built upon systems therapy and the relationship between HFNC therapy and clinical outcomes (e.g. 
PaO2, FiO2, vital signs, SpO2, etc.). The objective of this narrative review is to summarize research related to HFNC therapy. 
The research question to be considered is, “What clinical indices are positively impacted when using HFNC therapy for adult 
patients experiencing acute hypoxemic respiratory failure?” The aim of this narrative summary will extend beyond the clinical 
benefits of HFNC therapy and review the mechanism of action of HFNC therapy and the cautions during clinical application. 
Where appropriate, the article will compare HFNC therapy to conventional oxygen therapy and non-invasive ventilation 
strategies. For the purposes of this review, conventional oxygen therapy is referring to traditional low-flow (nasal cannula, non-
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rebreather mask, and simple O2 mask) and high-flow (venturi-mask) oxygen modalities. These devices provide supplemental 
oxygen therapy to patients requiring above ambient oxygen levels.  
  
METHODS 
A literature review was conducted in March of 2016 using a variety of databases (Medline, PubMed, and Google Scholar) with 
no limitation to publication year set. The open publication year was done primarily to include previous research that describes the 
basic principles of humidification and oxygen therapy. The study design of the literature search included clinical trials, bench-top 
research trials, clinical practice guidelines, and previously performed literature reviews. Only research publications written in 
English were included in this literature review. Keywords used in the search included high-flow nasal cannula, high-flow nasal 
cannula therapy, and humidified oxygen. Table 1 outlines the PICO (Patient, Intervention, Comparison, and Outcome) search 
criteria used for the literature review.  
 
PICO Criteria 
Patient All age group populations were considered for review in patients utilizing HFNC therapy who were 
experiencing acute respiratory failure.   
Intervention Previously published research was included if HFNC therapy was used to provide supplemental oxygen 
therapy for patients experiencing acute respiratory failure.  
Comparison Additional research was included in clinical situations where HFNC therapy was compared to non-invasive 
ventilation and traditional oxygen therapy.  
Outcome All patient-relevant outcomes of described interventions and comparisons where reviewed as part of this 
literature search.  
 
Literature search results were combined following completion of database searches. All duplicate articles were removed from the 
combined pool of gathered articles prior to review. Articles were initially considered for use based on a review of the title, abstract, 
and criteria outlined in the PICO search criteria. All remaining articles were reviewed by the authors for consideration for inclusion 
in this literature search.  
 
Quality Assessment 
Each article considered for use in the literature review was assessed for quality assurance. Impact factors (IF), Article Influence 
Scores (AIS), and Eigenfactor Scores (ES) were reviewed for each (Table 2).8 Only previously published peer-reviewed articles 
were used in this literature review.  
 
Journal Name Impact Factor Article Influence 
Score 
Eigenfactor 
Score 
Respiratory Care 1.92 55 77 
Clinical Medicine 1.65 43 54 
Minerva Anestesiologica 2.134 50 70 
Respiratory Medicine 3.036 76 91 
Intensive Care Medicine 10.125 93 95 
American Journal of Respiratory and Critical Care Medicinea 13.118 98 99 
Journal of Critical Care 2.445 68 82 
European Respiratory Journal 8.332 95 97 
Journal of Perinatology 2.087 68 82 
British Journal of Anesthesia 5.616 88 93 
Critical Care 4.95 92 97 
Journal of Intensive Care Medicine 3.262 N/A N/A 
Archives of Disease in Childhood 3.321 N/A N/A 
Surgery, Gynecology, and Obstetricsb 4.257 94 96 
a. Previously known as the American Review of Respiratory Disease Journal  
b. The journal has now changed its name to the Journal of the American College of Surgeons 
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RESULTS 
Results of the literature review revealed 520 combined “hits.” Duplicates and abstract only “hits” were removed from consideration. 
Remaining articles were assessed by the authors using the outlined PICO search criteria to fit the target goal of the literature 
review. All remaining articles post PICO search criteria were reviewed by the authors to assess the IF, AIS, and ES. All remaining 
articles post review were included in this literature review. Information from these articles includes details outlining study 
methodology and significance of research findings. Objective outcomes reported in this clinical review include changes in partial 
pressure of arterial oxygen (PaO2), pulse oximetry analysis, improvements in work of breathing, oxygenation index, and patient 
tolerance to HFNC therapy. The articles included in this publication add to the focus of this manuscript.  
 
HFNC Mechanism of Action 
High flow nasal cannula therapy can be applied to different age groups, encompassing a variety of different disease processes. 
The benefits of HFNC therapy are better understood with a discussion of the mechanisms of action. Dysart et al outlined the 
mechanisms of action into five categories: 1) a reduction of deadspace, 2) a reduction of resistance, 3) improved pulmonary 
mechanics, 4) a reduction of metabolic cost, and 5) distending airway pressure.9 Each of these mechanisms will be discussed 
below. 
 
High flow nasal cannula therapy systems are capable of providing oxygen flow rates that are significantly higher than traditional 
low flow nasal cannula devices.1 The delivery of high flow rates to the nasopharyngeal passages aids in the reduction in deadspace 
by creating tracheal gas insufflation (TGI).10 It has been reported that TGI further eliminates excess CO2 that remains in a patient’s 
airway on exhalation.11 Because of this removal, less CO2 will be re-inhaled by the patient on subsequent breaths.12 Wettstein et 
al researched the effects of open mouth breathing versus closed mouth breathing in patients using HFNC therapy.13 Their research 
discovered an increase in FiO2 in open mouth breathing patients. As a result, it was hypothesized that this increase in FiO2 was 
due to the reservoir effect of the nasal pharynx and oral cavity. It is believed that open mouth breathing while wearing a HFNC 
system allows for a more efficient elimination of CO2.13 Thus, HFNC therapy has the ability to washout CO2 and increase FiO2 
within the anatomical deadspace.  
 
Another mechanism of action of HFNC therapy includes a reduction of resistance in the patient’s nasopharyngeal passages. 
Patients experiencing respiratory failure often have an increase in work of breathing, elevated inspiratory flow rates and an increase 
in oxygen demands. Previous findings have reported a decrease in patient inspiratory flow rates in instances when high-flow 
oxygen therapy was used.14 The high oxygen flow rates delivered with HFNC therapy likely reduces inspiratory airway resistance 
by providing nasopharyngeal flow rates that exceed patient inspiratory demands.9 Vargas et al reported a reduction in inspiratory 
muscle effort and work of breathing in patients using HFNC therapy.15 Similarly, Sztrymf et al reported a significant reduction in 
work of breathing in patients experiencing respiratory failure when placed on heated HFNC therapy systems.16  
 
Previous research indicates that a lack of heated humidity to the nasopharyngeal passages can cause bronchoconstriction and a 
decrease in lung compliance.17 It has been reported that cold air delivered to the nasal cavity induced a vagally mediated 
bronchoconstriction in smoking, non-smoking, and patients diagnosed with COPD.18 The heated humidity provided in HFNC 
systems has been shown to improve pulmonary mechanics by effectively providing the patient with heated humidity at very high 
inspiratory flow rates. Ricard & Boyer reported better patient tolerance with oxygen flow rates of up to 60 lpm when the dry gas 
was heated and humidified.19 
 
Additional research reported an increased pulmonary compliance level in patients receiving HFNC therapy compared to patients 
using 6 cmH2O via continuous positive airway pressure.20 Chikata et al researched two HFNC therapy devices, the Airvo 2 and 
Optiflow system (Fisher & Paykel Healthcare, Auckland, New Zealand).21 The researchers tested humidity level at flow rates of 20, 
40 and 50 lpm. The absolute humidity levels for the Airvo 2 at 20, 40 and 50 lpm were 35.3  2.0 mg/L, 37.1  2.1 mg/L, and 37.6 
 2.1 mg/L, respectively. Results of the Optiflow indicated an absolute humidity level of 33.1  1.5 mg/L, 35.9  1.7 mg/L, and 36.2 
 1.8 mg/L at flow rates of 20, 40 and 50 lpm, respectively. The results of their research indicated that sufficient heated humidity 
was supplied at flow rates of up to 50 lpm in the two HFNC systems.  
 
Dysart et al reported a reduction in metabolic cost of gas conditioning in patients using HFNC therapy.9 Under normal respiratory 
conditions, inspired gases are heated and humidified by the nasopharyngeal passages until 100% relative humidity is obtained.22 
HFNC therapy provides heated humidified gases to the nasopharyngeal passages that would minimize the amount of energy 
exerted by the body to heat the delivered gas. It is estimated that an adult patient breathing 500 mls of gas at 12 breaths per minute 
burns 156 calories per minute warming and humidifying delivered dry gases.9 Previous research has indicated improved patient 
weight gain when placed on HFNC therapy.23 Furthermore, there is a reduced oxygen requirement associated with the delivery of 
heated humidified oxygen because of a reduced energy requirement by the patient’s body to warm and humidify the gas.9  
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Lastly, distal airway pressures are generated in patients using HFNC therapy that may contribute to a reduction in oxygen 
concentration requirements. Positive end-expiratory pressure generated in a patient’s airways will increase alveolar recruitment 
and increase a patient’s oxygenation status.24 In a comparison study, Corley et al researched the differences in end-expiratory 
lung volume and airway pressures when using low-flow and HFNC systems.25 Their findings indicated an increase of 25.6% in 
end-expiratory lung volume and pressure measurements of 3.0 cmH2O when switching from low-flow oxygen to HFNC therapy.25 
In a bench-top trial of HFNC therapy, Parke and McGuinness reported an elevation in expiratory pressure when using flow rates 
of 30, 40, and 50 lpm.26 Results of their research indicated flowrates of 30, 40, and 50 lpm produced airway pressures with a mean 
 SD of 1.93  1.25 cmH2O, 2.58  1.54 cmH2O, and 3.31  1.05 cmH2O, respectively. Further research by Parke et al reported 
pressure measurements when using flow rates up to 100 lpm. 27 Their findings report a mean  SD airway pressures of 2.7  0.7 
to 11.9  2.7 cmH2O when using flow rate ranges of 30 to 100 lpm.27  
 
Clinical Benefits of HFNC Therapy 
The available literature describes the therapeutic benefits of HFNC therapy. In a retrospective analysis, Nagata et al reviewed data 
from respiratory failure patients before and after the introduction of HFNC therapy.28 The study results demonstrated HFNC therapy 
significantly decreased the use of mechanical ventilation (invasive or non-invasive) in patients experiencing respiratory failure (p < 
.01). Also, a significant reduction in ventilator free days (p < .01) and ventilator required days (p < .05) was reported once HFNC 
therapy was introduced to the hospital. HFNC therapy did not reduce length of ICU/intermediate care unit days (p = .80), did not 
reduce hospital length of stay (p = .33), and did not increase hospital mortality rate (p = .26).28  
 
Roca et al revealed a clinical benefit when changing a patient from conventional facemask oxygen therapy to a HFNC device.5 
The research results revealed significant improvements in PaO2 (p = .002), respiratory rate (p <.001) and overall comfort (p <.001) 
when switched from oxygen therapy via facemask to HFNC. Additionally, patients given HFNC therapy demonstrated a significant 
decrease in dyspnea (p = .001) and dry mouth (p < .001). There were no significant changes in heart rate (p > .99) or mean arterial 
pressure (p > .36).5 
 
Parke et al also compared HFNC therapy to conventional facemask therapy.3 They reported HFNC therapy to be a more effective 
treatment for mild to moderate hypoxemic respiratory failure when compared to oxygen therapy via facemask.3 It was reported that 
patients using HFNC therapy had a reduction in need for non-invasive ventilation when compared to facemask therapy 
(HFNC=10%, Facemask = 3%, p=.10). Also, patients experienced significantly fewer (p=0.009) oxygen desaturation episodes 
when using HFNC therapy.3  
 
Rittayamai et al compared 6 lpm of oxygen via nasal cannula to 35 lpm of HFNC therapy.29 Results indicated levels of dyspnea 
significantly improved with HFNC therapy (p=.01). Patients using HFNC therapy reported reductions in breathing frequency (p=.82) 
and heart rate (p=0.04). Significant improvements (p=0.01) were reported in patient comfort levels when HFNC was compared to 
standard nasal cannula therapy.29  
 
Sztrymf et al compared HFNC therapy to a non-rebreather oxygen mask in patients experiencing acute respiratory failure.16 
Outcomes were assessed by monitoring patient heart rate, work of breathing, intercostal retractions, and oxygen parameters. 
Results indicated positive patient outcomes, in some instances as early as 15 minutes, after initiation of HFNC therapy. The authors 
reported HFNC significantly increased PaO2 (p=0.009) and PaO2/FiO2 (p=0.036) in comparison to the patient’s baseline 
oxygenation status. Results also indicated HFNC therapy was better tolerated by patients and decreased the patient’s work of 
breathing when compared to a conventional non-rebreather oxygen mask.16 
 
Vargas et al researched clinical outcomes in patients using a conventional non-rebreather mask, a continuous positive airway 
pressure (CPAP) level of 5 cmH2O and HFNC systems.15 The authors reported a significant reduction in inspiratory effort (p < .01) 
when patients were moved from a non-rebreather mask to either HFNC therapy or a CPAP level of 5 cmH2O. Also, patients showed 
a significant increase in PaO2/FiO2 ratio (p < .01) when switched from a non-rebreather to HFNC therapy. CPAP therapy revealed 
a significantly higher improvement in PaO2/FiO2 than HFNC therapy. It was also reported that patient’s respiratory rates 
significantly (p < .01) reduced when switched to HFNC. The reduction in respiratory rate from CPAP therapy to HFNC therapy was 
not significant.15  
 
Additional research compared HFNC therapy, non-invasive ventilation, and conventional non-rebreathing face mask. Results 
indicated a significant increase in PaO2 (p < .01) in patients moving from a conventional non-rebreathing face mask to HFNC 
therapy or to non-invasive ventilation. The PaO2/FiO2 ratio did not increase with HFNC therapy. It did, however, improve with non-
invasive ventilation (p < .01) when compared to HFNC therapy values. It was also reported that HFNC therapy was tolerated 
significantly better when compared to non-invasive ventilation (p = .004).6 
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Another area of study is the clinical benefit of HFNC therapy following extubation. Rittayamai et al compare short term benefits of 
HFNC and non-rebreather oxygen mask following the extubation of 17 patient volunteers.30 At the conclusion of the research, it 
was reported that patients using HFNC after extubation had a significant decrease in respiratory rate (p = .009), heart rate (p = 
.006), and shortness of breath (p = .04) when compared to a non-rebreather mask. Of the 17 patient participants, 88.2% preferred 
HFNC therapy over a non-rebreather mask following extubation. The research also reported no significant differences in oxygen 
saturation and mean arterial blood pressure between the participants using the two devices.21 In a similar study, Maggiore et al 
compared the benefits of HFNC versus an oxygen venturi-mask post-extubation.31 Their results demonstrated that patients using 
HFNC following extubation had a significant increase in PaO2/FiO2 ratio at the 24 (p = .03), 36 (p = .0003), and 48 (p = .01) hour 
marks. Also, significantly fewer patients required reintubation (p <.01) or non-invasive ventilation (p = .04) when using HFNC versus 
venture-mask.31 
 
Cautions of HFNC Therapy 
Despite the listed clinical benefits of HFNC therapy, clinical implementation of HFNC therapy needs to be carefully considered. 
One concern associated with HFNC therapy is delaying invasive and non-invasive ventilation after the initiation of HFNC therapy. 
Previous HFNC therapy research has failed to show a reduction in intubation rates in acute respiratory failure patients when 
compared to non-invasive ventilation. Kang et al enrolled 175 patients in a clinical trial investigating extubation rates and ICU 
mortality in patients using HFNC therapy.32 Research participants were classified into two groups based on intubation times after 
initiation of HFNC therapy (less than 48 hours or greater than 48 hours). Results indicated that patients intubated prior to 48 hours 
of initiation of HFNC therapy had better weaning outcomes (p = .002), better extubation success (p = .006), and better ICU mortality 
rates (p = .001). This research suggests that HFNC therapy may bring risk to the patient if more aggressive treatment options are 
delayed.32 A similar study by Frat et al investigated HFNC therapy as the initial therapy for non-hypercapnic hypoxemia.6 Results 
indicated 36% of patients experiencing acute respiratory failure required intubation after the use HFNC therapy. The authors 
reported a median intubation time of 30 hours after initiation of HFNC therapy. Symptoms of patients intubated in the study included 
worsening respiratory distress, respiratory arrest, and shock.6 
 
Research by Lemaile et al compared HFNC to high-flow facemask therapy via a venturi-mask.33 Their finding reported no significant 
difference in the need for invasive ventilation and non-invasive ventilation when comparing HFNC therapy to the use of a high-flow 
venturi-mask (p = .36).33 Of the 84 patients investigated, 52 received HFNC therapy, whereas 48 received oxygen therapy via 
venturi-mask. At the completion of a two-hour study period, 15% of HFNC therapy patients and 8% of venturi-mask patients 
required invasive or non-invasive ventilation. Moreover, there was no difference in heart rate (HFNC = 98 bpm, venturi - 99 bpm), 
respiratory rate (25 bpm), and dyspnea score (3) when comparing HFNC therapy to oxygen venturi-mask.33 
 
Research by Jones et al compared HFNC therapy to standard oxygen therapy.34 Standard oxygen devices included venturi-mask, 
Hudson aerosol mask, or nasal cannula.34 Starting flow rate for HFNC therapy was 40 lpm with an oxygen concentration of 28% 
at 37 C. Of the patients included in the research, 3.6 % of HFNC therapy patients and 7.8% standard oxygen patients required the 
use of non-invasive or invasive ventilation (p=.16). There was also no difference in emergency department length of stay (4.5 hours 
HFNC therapy, 4.9 hours in standard oxygen). Their research failed to show a reduction in non-invasive and invasive mechanical 
ventilation in patients experiencing acute respiratory failure in an emergency department when comparing HFNC therapy to 
standard oxygen.34  
 
IMPLICATIONS FOR FUTURE RESEARCH 
Further research is warranted to better understand the efficacy of HFNC therapy on a wide variety of pulmonary complications. 
Although promising research has been performed, clinical guidelines for HFNC therapy for specific patient disease processes has 
yet to be defined. Publications reviewed in this article focus primarily on acute respiratory failure patients. Further research is 
recommended to establish the efficacy of HFNC with a variety of different breathing patterns, heart rates, work of breathing, etc.  
 
In addition, further research is warranted to determine pressures and flowrates created at the alveolar level with HFNC therapy. 
Parke et al determined pressures generated by HFNC therapy by placing a catheter behind a patient’s uvula.35 Bench-top research 
is needed to determine positive end-expiratory pressure and inspiratory flowrates delivered to a patient’s distal airways.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
LIMITATIONS 
This paper provided a narrative review of the available research based on our search criteria. It provides an in-depth summary of 
the clinical outcomes associated with HFNC therapy and other oxygen delivery systems. Meta-analysis of data from the included 
studies was not the intention of this project.  
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CONCLUSION 
Information detailed in this article suggests HFNC therapy is an effective therapy for improving a patient’s oxygenation status when 
experiencing acute respiratory failure in adults. The literature reveals that it is reasonable to initiate HFNC in adults with acute 
hypoxemic respiratory failure without hypercapnia as an alternative to standard oxygen therapy or noninvasive positive pressure 
ventilation.36-38 The mechanism of action of HFNC therapy encompasses many therapeutic benefits for patients experiencing 
respiratory distress. Benefits include a reduction in work of breathing, increased patient tolerance of therapy, and an increase 
patient oxygenation. Additional research is warranted to understand the full scope of HFNC therapy.. 
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